- Exhibit & Support
- Travel & Hotels
Most patients with type 2 diabetes will require multiple pharmacologic agents as their disease progresses. For second-line therapy and beyond, clinicians now select among several treatment options—including insulin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 agonists, and sodium–glucose cotransporter 2 inhibitors. Although combination or coformulation products can simplify treatment regimens, identifying the best therapies for individual patients can still be daunting. Come explore proven strategies for effective second-line therapies for type 2 diabetes.
At the completion of this application-based activity, participants will be able to: